Short Summary
Harman International Industries and CasesTech have settled their dispute over U.S. Patent 8,805,692 and jointly moved to terminate the inter partes review. The motion cites statutory authority under 35 U.S.C. § 317(a) and requests confidentiality for the settlement agreement.
Detailed Summary
In IPR2024-01301 concerning U.S. Patent No. 8,805,692, Harman International Industries, Inc. and patent owner ST CasesTech, LLC have reached a settlement that resolves all disputes related to the patent. The parties filed a joint motion to terminate the inter partes review, invoking 35 U.S.C. § 317(a) and 37 C.F.R. § 42.74 to keep the settlement agreement confidential. The motion emphasizes public‑policy reasons for favoring settlement, the statutory requirement of a joint request before the Board decides the merits, and the efficiency and cost‑saving benefits of terminating the proceeding.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in HARMAN INTERNATIONAL INDUSTRIES, INC. vs ST CasesTech, LLC et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
SAMSUNG ELECTRONICS CO., LTD. et al.vsOMNI MEDSCI, INC.
Apple seeks to invalidate Omni MedSci’s wearable health‑monitor patent, arguing that all challenged claims are obvious over prior art. The petition requests the PTAB to institute an IPR and cancel the claims.
Intelligent Wellhead Systems, Inc. et al.vsDowning Wellhead Equipment, LLC et al.
The USPTO denied Intelligent Wellhead Systems' request for Director Review of the institution decision on its wellhead patent, keeping the institution in place.
Sarepta Therapeutics, Inc. et al.vsGenzyme Corporation et al.
The USPTO Board denied the institution of IPR proceedings (IPR2025-01194) involving Sarepta Therapeutics and Genzyme Corporation, meaning no trial will proceed on the challenged patent.
Imperative Care, Inc.vsInari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after Imperative Care showed a reasonable likelihood of success, focusing on the definition of “filament” and its flexibility versus prior art.
Niantic, Inc.vsImagineAR, Inc. et al.
Niantic has filed an IPR petition challenging all 28 claims of ImagineAR’s U.S. Patent No. 11,666,827, which covers location‑based virtual gameplay. The challenger asserts that the claims are obvious over the Kolo and Zyda references under 35 U.S.C. §103 and seeks cancellation of the entire patent.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.